AZN - Spark Newswire

1 minute read

Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022

November 9, 9:23 AM

On CNBC's "Options Action," Michael Khouw of Optimize Advisors said that AstraZeneca plc. (NASDAQ: AZN) traded 3.9 times its average daily put volume on Tuesday.

AZN

2 minute read

FDA
News

AstraZeneca Announced PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

By Charles Gross

November 9, 5:47 AM

The Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older.

AZN

1 minute read

Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio

By Vandana Singh

November 8, 1:26 PM

Avenue Therapeutics Inc (NASDAQ:ATXI) acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc (NASDAQ:FBIO).…

ATXI

1 minute read

Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants

By Vandana Singh

November 4, 7:37 AM

The European Commission has approved AstraZeneca plc (NASDAQ:AZN) and Sanofi SA’s (NASDAQ:SNY) Beyfortus (nirsevimab) long-acting antibody to prevent respiratory syncytial virus (RSV) lower…

AZN

6 minute read

Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

November 1, 4:01 PM

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

APLS

12 minute read

15 Global Psychedelics Executives To Keep An Eye On In 2022

By Javier Hasse

October 28, 12:35 PM

As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list of some of the top executives in the space to keep an eye on.

ACB

1 minute read

AstraZeneca’s Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord

By Vandana Singh

October 27, 10:44 AM

AstraZeneca Plc (NASDAQ:AZN) posted detailed results from the Phase 3 CHAMPION-NMOSD trial of Ultomiris (ravulizumab) For neuromyelitis optica spectrum disorder (NMOSD). NMOSD…

AZN

4 minute read

Invitae Announces Partnership For Real-World Data Sharing To Inform Rare Cancer Research

By Benzinga Newsdesk

October 27, 7:36 AM

– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – –

AZN

3 minute read

News

AstraZeneca Announced Ultomiris Showed Zero Relapses in Adults With Neuromyelitis Optica Spectrum Disorder With Median Treatment Duration of 73 Weeks

By Charles Gross

October 27, 4:45 AM

Results from CHAMPION-NMOSD trial demonstrated Ultomiris reduced the risk of relapse in AQP4 Ab+ NMOSD by 98.6% compared to placebo. Ultomiris also showed a lower proportion of patients experiencing clinically important worsening in Hauser Ambulatory Index score, a measure of patient mobility.

AZN

4 minute read

Intel’s Self-Driving Tech Firm Raises Over $800M In IPO, Alphabet Misses Q3 Earnings Expectations, Lyft Cuts Price For Monthly Subscription Plan: Top Stories Wednesday, Oct. 26

By Vandana Singh

October 26, 9:15 AM

Benzinga

AZN

Feed Symbols: AZN